- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S2796
| Related Targets | EGFR STAT Pim |
|---|---|
| Other JAK Products | BMS-986165 (Deucravacitinib) AZD1480 Momelotinib (CYT387) Filgotinib (GLPG0634) AT9283 Gandotinib (LY2784544) TG101209 Cerdulatinib (PRT062070) hydrochloride Pacritinib NVP-BSK805 2HCl |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| human MM1 cells | Function assay | 24-72 h | Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, ic50=1.2 μM | |||
| human U266 cells | Function assay | 24-72 h | Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay, IC50=1.5 μM | |||
| human OCI-My4 cells | Function assay | 24-72 h | Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay, IC50=1.8 μM | |||
| human 30M cells | Cytotoxic assay | 8 days | Cytotoxicity against human 30M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=1.8 μM | |||
| human 73M cells | Cytotoxic assay | 8 days | Cytotoxicity against human 73M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=2.1 μM | |||
| human U373MG cells | Function assay | 24-72 h | Antitumor activity against human U373MG cells after 24 to 72 hrs by MTT assay, IC50=3.7 μM | |||
| human U87MG cells | Function assay | 24-72 h | Antitumor activity against human U87MG cells after 24 to 72 hrs by MTT assay, IC50=5.6 μM | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 71 mg/mL
(199.31 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 356.22 | Formula | C17H14BrN3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 857064-38-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N | ||
| Features |
Similar to its parent compound AG490, WP1066 inhibits the phosphorylation of JAK2, but unlike AG490, WP1066 also degraded JAK2 protein.
|
|---|---|
| Targets/IC50/Ki |
JAK2
(HEL cells) 2.3 μM
STAT3
(HEL cells) 2.43 μM
|
| In vitro |
WP1066 markedly inhibits the growth of HEL cells carrying the JAK2 V617F mutant isoform in a dose-dependent manner with IC20, IC50 and IC80 of 0.8, 2.3 and 3.8 μM. This compound at concentrations of 0.5, 1.0, 2.0, 3.0, or 4.0 μM inhibits the phosphorylation of JAK2, STAT3, STAT5, and ERK1/2 without affecting the phosphorylation of JAK1 and JAK3 in erythroid leukemia HEL cells that express the JAK2 V617F isoform. It at concentrations ranging from 0.5 to 3.0 μM inhibits the proliferation of AML colony-forming cells obtained from patients and that of the AML cell lines OCIM2 and K562 in a dose-dependent manner. This chemical at concentrations of 0.5, 1.0, 2.0, 3.0, or 4.0 μM dose-dependently decreases JAK2 and pJAK2 protein levels as well as downstream phosphorylation levels of STAT3, STAT5, and AKT in OCIM2 and K562 cells. It at concentrations of 2 μM inhibits OCIM2 cell multiplication by inducing accumulation of cells at the G0-G1 phase of the cell cycle. This compound at concentrations of 1, 2, or 3 μM induces apoptosis in both OCIM2 and K562 cells in a dose-dependent fashion by activating procaspase-3 and cleaving PARP. It at concentrations of 5 μM prevents the phosphorylation of STAT3, and at concentrations of 2.5μM it significantly inhibits cell survival and proliferation in Caki-1 and 786-O renal cancer cells. This chemical at concentrations of 5 μM suppresses HIF1α and HIF2α expression and VEGF production in Caki-1 and 786-O renal cancer cells.
|
| In vivo |
WP1066 orally administrated at dose of 40 mg/kg once daily for 19 days significantly inhibits the tumours growth in Caki-1 xenograft mice, with decreased immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-STAT3 / STAT3 / p-ERK / ERK |
|
20461084 |
| Cell viability | Cell viability |
|
28496056 |
| Immunofluorescence | N-cadherin / E-cadherin / Vimentin / β-catenin |
|
26690371 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04334863 | Completed | Brain Tumor|Medulloblastoma|Brain Metastases |
Emory University|CURE Childhood Cancer Inc.|Peach Bowl LegACy Fund |
May 4 2020 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.